Ricerca avanzata

Home > Riviste > Minerva Medica > Fascicoli precedenti > Minerva Medica 2014 Dicembre;105(6 Suppl 2) > Minerva Medica 2014 Dicembre;105(6 Suppl 2):9-16



Rivista di Medicina Interna

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236

Periodicità: Bimestrale

ISSN 0026-4806

Online ISSN 1827-1669


Minerva Medica 2014 Dicembre;105(6 Suppl 2):9-16


FlexiQule (Boswellia extract) in the supplementary management of osteoarthritis: a supplement registry

Belcaro G., Dugall M., Luzzi R., Ledda A., Pellegrini L., Cesarone M. R., Hosoi M., Errichi M., Francis S., Cornelli U.

Department of Biomedical Sciences Irvine3 Labs, Circulation Sciences and the International Irvine Network, Chieti‑Pescara University, Italy

The aim of the present pilot, registry study was an assessment in a supplement study of FlexiQule (standardized Boswellia extract) capsules in the supplementary management of patients with symptomatic knee osteoarthritis (OA) also treated with the “standard management” (SM) in comparison with a group of patients only managed with SM.
Methods. This 4-week study included patients with symptomatic knee arthrosis (X-ray). Registry subjects were able to perform a treadmill walking test and to understand questions from the WOMAC questionnaire. Exclusion criteria were conditions requiring drug treatment, Body Mass Index >25, metabolic disorders, surgery within three months prior to inclusion, oncological condition or inability to walk.
Results. Twenty-seven registry subjects using the supplement+SM and 28 using only SM completed the registry; at inclusion, the two groups were comparable including Karnofsky scale, WOMAC Score and the Treadmill Test. Of the subjects completing the registry 24 preferred to use the combination SM and the supplement. Safety evaluation: no problems – indicating the suspension of the supplementation ‑ were observed. Routine blood tests were normal at inclusion and did not significantly vary at 4 weeks. The Karnofski Scale at 4 weeks was improved in both groups: from 74.3;3.1 to 88.9;5.3 (P<0.05) in the Boswellia group in comparison with a variation from 75.3;5.2 to 79.4;3.3 (P<0.05) in the SM. The effects of the supplement were significantly higher (P<0.05). The WOMAC Score was decreased significantly more in the supplement+SM group in comparison with controls considering pain, stiffness and physical functions (P<0.05). Social/emotional functions improved better with the supplement (P<0.05). Both groups improved their walking distance at 4 weeks. The improvement was higher (P<0.05) in the Boswellia group. The need for other drugs or tests during the registry period was reduced more in the supplement group (P<0.05).
Conclusion. The difference between SM and the supplementation associated to SM was significant) in favor of the supplementation with Boswellia for all target measurements evaluated in the registry at 4 weeks.

lingua: Inglese


inizio pagina